Skip to main content

Canaccord Genuity Reaffirms Their Buy Rating on Adicet Bio (ACET)

Tipranks - Tipranks - Fri Nov 7, 2025

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Adicet Bio, with a price target of $8.00.

Meet Your ETF AI Analyst

Newman covers the Healthcare sector, focusing on stocks such as Delcath Systems, Arcellx Inc, and Regeneron. According to TipRanks, Newman has an average return of -1.6% and a 36.60% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $6.50 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Adicet Bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $26.86 million. In comparison, last year the company had a GAAP net loss of $30.48 million

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACET in relation to earlier this year.

Read More on ACET:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).